Skip to content

Biohaven Pharmaceutical Holding Company Ltd.

CIK 0001689813

← back to feed
Revenue (TTM)
$762.6M
+1,217.2% YoY Q2 Aug 2022
Net Income (TTM)
−$842.59M
−288.8% YoY Q2 Aug 2022
EPS Diluted (TTM)
−$15.04
−0.2% YoY Q2 Aug 2022
Gross Margin
30.2%
Q2 Aug 2022
Operating Margin
-85.9%
Q2 Aug 2022
Net Margin
-110.5%
Q2 Aug 2022
Free Cash Flow (TTM)
−$430.66M
Q2 Aug 2022
Cash
$235.81M
Q2 Aug 2022
Total Debt
$619.27M
Q2 Aug 2022
Shares Outstanding
71.49M sh
Q2 Aug 2022

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings